LivaNova (NASDAQ:LIVN) Reaches New 12-Month High – Still a Buy?

LivaNova PLC (NASDAQ:LIVN)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $85.45 and last traded at $85.1840, with a volume of 750889 shares traded. The stock had previously closed at $82.46.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LIVN. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Mizuho increased their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.38.

LivaNova Stock Performance

The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The business has a 50 day moving average price of $79.26 and a two-hundred day moving average price of $70.33. The company has a market cap of $4.69 billion, a P/E ratio of 43.75 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the prior year, the company posted $0.88 EPS. LivaNova’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LIVN. Hantz Financial Services Inc. increased its stake in LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming purchased a new stake in LivaNova during the second quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its holdings in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP purchased a new position in shares of LivaNova in the 3rd quarter worth approximately $36,000. Finally, Covestor Ltd raised its stake in shares of LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after acquiring an additional 392 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.